CSPC Secures US$25.00 Million R&D Milestone from AstraZeneca in Long-Acting Peptide Collaboration

Bulletin Express

07/10

CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026.

The payment arises from the strategic collaboration and licence agreement signed on 30 January 2026, which combines CSPC’s proprietary sustained-release delivery and AI-driven peptide discovery platforms with AstraZeneca’s global development and commercial capabilities. An upfront payment was previously received on 29 May 2026.

Management stated that achievement of this milestone confirms that development activities for the licensed long-acting peptide medicines are advancing in line with plan.

The companies will continue joint development, manufacturing and commercialisation efforts, although CSPC cautions that project outcomes remain subject to customary R&D uncertainties. Further material updates related to the agreement will be disclosed as appropriate.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1123700250"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1123700250\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1123700250?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-10 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1123700250","market":"hk","top_or_hot":-1,"title":"CSPC Secures US$25.00 Million R&D Milestone from AstraZeneca in Long-Acting Peptide Collaboration","media":"Bulletin Express","content":"<p>CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026.</p>\n<p>The payment arises from the strategic collaboration and licence agreement signed on 30 January 2026, which combines CSPC’s proprietary sustained-release delivery and AI-driven peptide discovery platforms with AstraZeneca’s global development and commercial capabilities. An upfront payment was previously received on 29 May 2026.</p>\n<p>Management stated that achievement of this milestone confirms that development activities for the licensed long-acting peptide medicines are advancing in line with plan.</p>\n<p>The companies will continue joint development, manufacturing and commercialisation efforts, although CSPC cautions that project outcomes remain subject to customary R&D uncertainties. Further material updates related to the agreement will be disclosed as appropriate.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSPC Secures US$25.00 Million R&D Milestone from AstraZeneca in Long-Acting Peptide Collaboration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSPC Secures US$25.00 Million R&D Milestone from AstraZeneca in Long-Acting Peptide Collaboration\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-10 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026.</p>\n<p>The payment arises from the strategic collaboration and licence agreement signed on 30 January 2026, which combines CSPC’s proprietary sustained-release delivery and AI-driven peptide discovery platforms with AstraZeneca’s global development and commercial capabilities. An upfront payment was previously received on 29 May 2026.</p>\n<p>Management stated that achievement of this milestone confirms that development activities for the licensed long-acting peptide medicines are advancing in line with plan.</p>\n<p>The companies will continue joint development, manufacturing and commercialisation efforts, although CSPC cautions that project outcomes remain subject to customary R&D uncertainties. Further material updates related to the agreement will be disclosed as appropriate.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01093","symbol_name":"石药集团","start_time":0,"source_url":"","article_id":"1123700250","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1123700250","pubTimestamp":1783694548,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026. The payment arises from the strategic...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01093":"石药集团"},"translate_title":"石药集团从阿斯利康获得2500万美元长效肽合作研发里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":1},"content_text":"CSPC Pharmaceutical Group Limited (CSPC) announced receipt of a US$25.00 million research and development milestone payment from AstraZeneca on 10 July 2026.\nThe payment arises from the strategic collaboration and licence agreement signed on 30 January 2026, which combines CSPC’s proprietary sustained-release delivery and AI-driven peptide discovery platforms with AstraZeneca’s global development and commercial capabilities. An upfront payment was previously received on 29 May 2026.\nManagement stated that achievement of this milestone confirms that development activities for the licensed long-acting peptide medicines are advancing in line with plan.\nThe companies will continue joint development, manufacturing and commercialisation efforts, although CSPC cautions that project outcomes remain subject to customary R&D uncertainties. Further material updates related to the agreement will be disclosed as appropriate.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}